IGF2 and neoplasm: Clinical trials are warranted to assess whether therapeutic strategies targeting STAT3 or IGF-2 would circumvent tumour angiogenesis and pro-invasive consequences, overcoming innate resistance to anti-IGF-1R monoclonal antibody-based therapies.